Advisors Preferred, LLC Regeneron Pharmaceuticals, Inc. Transaction History

Advisors Preferred, LLC

  • $645 Million
  • Q3 2024

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 07, 2022
SELL
$573.97 - $724.32 $164,155 - $207,155
-286 Reduced 26.17%
807 $593,000
Q2 2022

Aug 11, 2022
SELL
$548.35 - $738.84 $3.7 Million - $4.99 Million
-6,749 Reduced 86.06%
1,093 $646,000
Q1 2022

May 09, 2022
BUY
$595.12 - $698.43 $1.46 Million - $1.71 Million
2,450 Added 45.44%
7,842 $5.45 Million
Q4 2021

Feb 07, 2022
BUY
$543.48 - $670.97 $1.78 Million - $2.19 Million
3,269 Added 153.98%
5,392 $3.38 Million
Q3 2021

Oct 27, 2021
BUY
$574.03 - $680.96 $1.22 Million - $1.45 Million
2,123 New
2,123 $1.21 Million
Q2 2021

Jul 26, 2021
SELL
$472.8 - $558.54 $1.79 Million - $2.11 Million
-3,785 Closed
0 $0
Q1 2021

May 07, 2021
BUY
$446.73 - $548.2 $1.69 Million - $2.07 Million
3,785 New
3,785 $1.8 Million
Q4 2020

Feb 03, 2021
SELL
$478.3 - $607.98 $1.01 Million - $1.29 Million
-2,121 Closed
0 $0
Q3 2020

Nov 12, 2020
BUY
$544.75 - $658.21 $295,254 - $356,749
542 Added 34.33%
2,121 $1.19 Million
Q2 2020

Aug 11, 2020
BUY
$493.32 - $643.92 $778,952 - $1.02 Million
1,579 New
1,579 $962,000
Q1 2020

Apr 20, 2020
SELL
$336.18 - $494.43 $520,070 - $764,883
-1,547 Closed
0 $0
Q4 2019

Jan 21, 2020
BUY
$274.13 - $376.51 $424,079 - $582,460
1,547 New
1,547 $581,000

Others Institutions Holding REGN

# of Institutions
1,534
Shares Held
83.6M
Call Options Held
1.22M
Put Options Held
1.51M
View Full List

About REGENERON PHARMACEUTICALS, INC.

REGN Quotes by TradingView
  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $75.3B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Advisors Preferred, LLC Portfolio

Follow Advisors Preferred, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisors Preferred, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Advisors Preferred, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email